Orforglipron reduced HbA1c more than oral semaglutide in T2D at 52 weeks.

Type 2 diabetes (T2D) is a progressive metabolic disorder characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to chronic hyperglycemia. While metformin is a first-line therapy, many patients require additional interventions to achieve optimal glycemic control. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized T2D management due to their potent glucose-lowering effects, weight loss benefits, and established cardio-renal protection. Although injectable GLP-1 RAs are widely used, oral formulations, such as oral semaglutide, offer improved patient convenience and adherence. However, there remains a critical need for even more efficacious and accessible oral options, particularly for individuals whose HbA1c remains elevated despite current treatments. Small molecule GLP-1 RAs, like orforglipron, represent a promising class of oral agents that could offer enhanced efficacy and broader accessibility compared to existing peptide-based oral formulations.

This was a Phase 3, randomized, open-label study (ACHIEVE-3, NCT06045221) designed to investigate the efficacy and safety of once-daily oral LY3502970 (orforglipron) compared with oral semaglutide. The study enrolled adult participants diagnosed with type 2 diabetes who had inadequate glycemic control despite ongoing metformin therapy. Participants were randomized to receive either orforglipron or oral semaglutide, with the primary endpoint being the change in HbA1c from baseline after 52 weeks of treatment. The open-label design meant that both participants and investigators were aware of the assigned treatment arm. Secondary endpoints, including body weight changes and safety profiles, were also assessed.